The Effects of Plasma Homocysteine in PCOS Women: A Review

Pranita Maharjan, Peng Dan Hong*

Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing, China
Email: *pranimrj@gmail.com

Abstract

Homocysteine is an intermediate substance formed during the breakdown of the amino acid methionine and may undergo remethylation to methionine or trans-sulfuration to cystathionine or cysteine. The metabolism occurs via two pathways: remethylation to methionine, which requires folate and vitamin B12; and transsulfuration to cystathionine, which requires pyridoxal-5'-phosphate. The disturbances in the metabolic pathways lead to the accumulation of Hcy, either by insufficient transsulfuration (through CBS mutations or vitamin B6 deficiency) or by a blockage of remethylation. In the latter case, folate or vitamin B12 deficiency may be involved, as well as MTHFR. High levels of Hcy induce sustained injury of arterial endothelial cells, proliferation of arterial smooth muscle cells and enhance activity of key participants in vascular inflammation, atherogenesis, and vulnerability of the established atherosclerotic plaque. Hyperhomocysteinemia has become the topic of interest in recent years. It has been highly associated with increased risk for cardiovascular disorders, such as, atherosclerosis, thromboembolism and dyslipidemia. Women with PCOS show constellation of metabolic syndromes. Obesity, hyperandrogenemia and type 2 diabetes mellitus is the hallmark of PCOS which later becomes the risk factors for cardiovascular disease. Various studies had revealed the presence of increased Hcy level in PCOS women which may or may not be associated with other biochemical parameters. Intense treatment for PCOS can influence homocysteine levels.

Keywords

Polycystic Ovary Syndrome, Homocysteine, Insulin Resistance

1. Introduction

Polycystic ovary syndrome (PCOS) proves as the most common endocrine dis-
order with a prevalence of 5% to 15% worldwide [1], for the women of active reproductive age, but the prevalent rate varies depending on the criteria used for the diagnosis [2] [3]. According to the Rotterdam diagnostic criteria, the prevalence rate of PCOS accounts up to 18% of reproductive-aged women [2] [3], whilst the prevalence rate is 10% when using NIH criteria for diagnosis criteria [3] but the prevalence is still unknown in children [2] [4]. Three different criteria have been implemented for the diagnosis of PCOS: the NIH criteria (1990), the Rotterdam criteria (2003) and the Androgen and PCOS society (AE-PCOS) criteria (2006) [5] [6]. Amongst the three criteria, the Rotterdam criterion was adopted as the Practice Guidelines of the Endocrine Society [2] [7]. The Rotterdam criteria comprise features as, chronic menstrual dysfunction, clinical or biochemical hyperandrogenism and polycystic ovaries confirmed by ultrasonography (≥10 follicles and ≥10 ml ovarian volume) [8]. The etiology of PCOS still remains unclear but various predisposing genes interfere with environmental and lifestyle manners [5] [9], makes PCOS a complex genetic disorder. The constellations of symptoms significantly affect the quality of life of PCOS women and the syndrome is associated with an increased long term risk factors such as cardiovascular disease, diabetes mellitus, infertility, cancer and psychological disorders [10].

In current years, homocysteine, a biosynthesis of methionine has proved as a major cardinal feature of PCOS. It is a non-protein a-amino acid and cysteine homologue. Its metabolic pathway encompasses either remethylation to methionine or through transsulfuration to cystathionine as shown in Figure 1 [11]. The first metabolism pathway requires folate and vitamin B12 whereas the latter requires pyridoxal-5’-phosphate. S-adenosylmethionine (SAM) augments the synthesis of both pathways which is a moderator of methylenetetrahydrofolate reductase (MTHFR) and inhibitor of cystathionine β-synthase (CBS). The metabolic

Figure 1. Homocysteine metabolism, ref. [11].
pathways are interrupted by any impaired function either by insufficient trans-sulfuration through CBS mutation or deficiency of vitamin B6 or secondly by remethylation blockage, can lead to abnormal accumulation of plasma Hcy. In the latter case, the accumulation of homocysteine could be due to deficiency of folate or vitamin B12, as well as MTHFR [12]. A condition that emerges from disrupted homocysteine metabolism is hyperhomocysteinemia which has been known as the most significant risk factor for cardiovascular disease and has been confirmed by recently conducted meta-analysis study by Homocysteine Studies Collaboration [13]. Deficiencies in cystathionine beta synthase, methylenetetrahydrofolate reductase or enzymes involving methyl-B12 synthesis, as a result of a rare genetic defect, lead to severe hyperhomocysteinemia. In fasting status, due to mild impairment in the methylation mechanism (i.e. folate or B12 deficiencies or MTHFR thermolability), occurs mild hyperhomocysteinemia [12]. Homocysteine play a role as a mediator for endothelial damage and dysfunction [14] that subsequently impairs endothelial vasoreactivity and decrease endothelium thromboresistance. Hence, hyperhomocysteinemia associated with increased risk of atherosclerosis, thromboembolic diseases and hyperinsulinemia is verified which is directly proportionate to increased risk of cardiovascular disorders with a strong correlation to insulin resistance. Hyperhomocysteinemia also aggravates the incidence of late pregnancy complications, such as preeclampsia, abruption placentae, preterm birth and intrauterine fetal death [15]. Hyperhomocysteinemia is also one of the major factors that leads to early miscarriages by impairing by interfering endometrial blood flow and vascular integrity [16] and also described as the sole variable resulting in recurrent pregnancy loss [17].

According to numerous clinical studies, PCOS in women is associated with existence of endothelial and platelet dysfunction, minimal chronic inflammation, increased coronary artery calcification and carotid intima-media thickness in PCOS women [18]. PCOS women are highly susceptible to both cardiovascular risk factors, such as, obesity dyslipidemia, hypertension and type-2 diabetes mellitus, and mood disorders, such as depression and anxiety [2].

2. Homocysteine Status and Association with Other Biochemical Properties

There are numbers of studies conducted and have confirmed the fact that the plasma Hcy level is significantly raised in women with PCOS. However, few studies fail to affirm obvious changes in the plasma homocysteine level (Table 1). A case-control study conducted in the year 2016 showed that the serum homocysteine levels were significantly high in PCOS women. According to the study, obese women had a higher concentration of plasma Hcy (13.19 ± 5.42 µmol/L) than non-obese women (9.38 ± 2.99 µmol/L) with p-value < 0.02, regardless the participants suffer from PCOS or not [19]. Similarly, a prospective study among 339 women, 84 women had hyperhomocysteinemia with cut off value > 12.4 µmol/L and the factor associated to increase the plasma Hcy level was known to be elevated serum total testosterone [20]. The study also reported that
Table 1. Homocysteine level in PCOS women.

<table>
<thead>
<tr>
<th>Increased Hcy level</th>
<th>No significant changes in Hcy level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mahtab Moti et al. 2015 [37] (Iran), n = 30, p &lt; 0.001</td>
<td>Sills et al., 2001 [45] (USA), n = 36, p &lt; NS</td>
</tr>
<tr>
<td>Sachan Rekha et al. 2014 [23] (India), n = 50, p &lt; 0.001</td>
<td>Morgante et al., 2002 [46] (Italy), n = 20, p &lt; NS</td>
</tr>
<tr>
<td>Murat Yilmaz et al. 2005 [40] (Turkey), n = 50, p &lt; 0.005</td>
<td>orio et al., 2003 [47] (Italy), n = 70, p &lt; NS</td>
</tr>
<tr>
<td>Tayeb Hemati et al. 2011 [25] (Iran), n = 64, p &lt; 0.001</td>
<td>Mancini et al., 2009 [48] (Italy), n = 20, p &lt; NS</td>
</tr>
<tr>
<td>Morey Schacter et al. 2003 [26] (Israel), n = 155, p &lt; 0.0001</td>
<td>Arian et al., 2010 [49] (Turkey), n = 31, p &lt; NS</td>
</tr>
<tr>
<td>Priyanka Maleedhu et al. 2014 [41] (India), n = 142, p &lt;&lt; 0.0001</td>
<td>Moini et al., 2011 [50] (Iran), n = 123, p &lt; 0.157</td>
</tr>
<tr>
<td>Mohamadin et al., 2010 [42] (Saudi Arabia), n = 50, p &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>Karaer et al., 2010 [43] (Turkey), n = 31, p = 0.04</td>
<td></td>
</tr>
<tr>
<td>Pamuk et al., 2010 [44] (Turkey), n = 35, p = 0.02</td>
<td></td>
</tr>
<tr>
<td>Rajagopal et al., 2011 [38] (India), n = 25,</td>
<td></td>
</tr>
<tr>
<td>Kilic-Okman et al., 2004 [27] (Turkey), n = 29, p = 0.001</td>
<td></td>
</tr>
</tbody>
</table>

Hyperhomocysteinemia was identified with biochemical hyperandrogenism but not with clinical hyperandrogenism i.e., hirsutism. Previously, Carmina et al. found significant rise in plasma Hcy level in classic hyperandrogenism with chronic anovulatory PCOS women [21]. A case control study conducted in infertile women found significantly higher level of follicular fluid Hcy in PCOS women that may affect pregnancy outcome undergoing assisted reproduction suggesting of poor oocyte and embryo quality and decreased fertilization rate [22]. The elevated follicular fluid Hcy was not related to parameters such as E2 and glucose level, BMI and age.

Recent research by Sachan Rekha et al. have reported significant higher serum Hcy level in PCOS women, remarkably increased in both obese and non-obese PCOS women and it was best correlated with HOMA-IR out of three indices used for IR [23]. Likewise, other few studies supports that the raised plasma Hcy is correlated with insulin resistance [24]-[34]. Insulin and homocysteine is known to influence each other. A case-control study in adolescent have demonstrated significant increase in serum Hcy level with no difference noted between obese and non-obese PCOS and was positively correlated with IR. Correspondingly, Sedigheh Esmaeilzadeh et al. and Rosolova et al. unexpectedly found inverse relationship between Hcy levels and IR [35] [36]. On contrary, few authors have demonstrated that serum Hcy level is not associated with IR [19] [20] [37] [38] [39].

3. Influence on Hcy Level Post PCOS Therapy

Insulin and Hcy have the ability to induce each other by inhibiting hepatic CBS [23] that results in hyperhomocysteinemia leading to compensatory hyperinsulinemia by inducing insulin resistance. This may impair activity of the MTHFR or CBS enzymes, leading to abnormal deposition of homocysteine in plasma [24] [51] [52]. This explains that insulin resistance may be the most important mark-
er of metabolic disease in PCOS women [53]. Hence, metformin has always been the mainstay treatment for PCOS women with insulin resistance. With administration of metformin, some study has shown beneficial decrease in plasma Hcy level [8] [54]. Nonetheless, it is also studied that metformin monotherapy is unsatisfactory [55]. The study conducted by Vrbikova et al. revealed that the treatment with metformin only may increase the plasma Hcy level [56]. Administration with rosiglitazone and metformin seem to decrease elevated oxidative stress compared to metformin treatment but no significant changes were observed in plasma Hcy [40]. Kiliçdag et al. also reported the same result [57]. This statement can be explained by folate depletion and malabsorption of vitamin B12 [58] [59] that disturbs Hcy metabolism, thus, supplementation with folate can be preventative [57] [60]. Moreover, treatment with metformin and cyclic medroxyprogesterone acetate (MPA) also tend to increase Hcy level [55]. Stefano Palombo et al. reported that treatment with metformin can slightly reduce the Hcy level in PCOS women, but supplementation with folate has shown to increase the beneficial effect [60]. Hence, folate supplementation is the first therapeutic measure advised in obese PCOS patients that prevents rise in Hcy level during weight loss. A prospective randomized clinical study in 2010, in both obese and non-obese PCOS women, observed dramatic decrease in plasma Hcy level when treated with metformin. However, the study in the both group when treated with oral contraceptives increased the plasma Hcy level and other biochemical parameters that increased the metabolic risk [61].

Statins have also been administered and seems to deplete serum Hcy levels in PCOS [48] [62]. In a prospective cohort study, the combination of ethinyl estradiol/drospirenone (EE-DRSP) and spironolactone treatment were given to lean and glucose tolerant patients with PCOS for 6 months, improved androgen excess but the combination increased Hcy level and CRP level [63]. Similarly, oral contraceptives containing 0.03 mg ethinyl estradiol and 0.15 mg desogestrel for 6 months had significantly decreased Hcy level in non-obese normoandrogenic PCOS patients [61]. Furthermore, oral contraceptives containing 35 µg ethinyl estradiol and 2 mg cyproterone acetate had resulted in rapid decrease in Hcy level in non-smoking PCOS women [64] [65] [66], whereas Hcy level remains high in the smokers. It has also been studied that Hcy levels decreased after regular exercises for 6 months [67] and also have shown to decrease 3 months after ovarian surgery [68]. The treatment of above mentioned studies are summarized in the tables (Tables 2-4).

4. Conclusion

PCOS, also known as Stein-Leventhal syndrome, is not only a gynecological disorder, but a sequence of endocrine disorder amongst women in reproductive age, metabolic imbalance such as insulin resistance and dyslipidemia, associated chemical and biochemical hyperandrogenemia that optimally results in psychological disorder. PCOS has been the topic of debate since many decades with greater evidence of Hcy metabolism disturbances. The raised plasma homocysteine
have been extensively approved as an absolute risk factor for cardiovascular disease. Basal Hcy level is gradually increased after menopause that explains the cardiovascular risk burden and can be prevented in some extents by hormone replacement therapy [69]. There is still need of further study to gain clear knowledge about the role of homocysteine in PCOS and to clarify the relationship between insulin resistance, androgen levels and other biochemical parameters, thus, enlightening the better treatment options and avert women from short and long term risk factors such as cardiovascular disease, type 2 diabetes mellitus,
infertility, recurrent miscarriages and psychological disorder. Once obtained the desired goal, women with PCOS can thus lead a better quality of life.

References


DOI: 10.4236/ojog.2018.81005


The Effects of Rosiglitazone and Metformin on Oxidative Stress and Homocysteine Levels in Lean Patients with Polycystic Ovary Syndrome. *Human Reproduction, 20*, 3333-3340. [https://doi.org/10.1093/humrep/dei258](https://doi.org/10.1093/humrep/dei258)


Abbreviations

PCOS: Polycystic Ovary Syndrome
NIH: National Institute Health
Hcy: Homocysteine
HOMA-IR: Homeostasis Model Asssessment-Insulin resistance
SAM: S-adenosylmethionine
MTHFR: Methylenetetrahydrofolate reductase
CBS: Cystathionine Beta Synthase
E2: Estradiol
BMI: Body mass index
MPA: Medroxyprogesterone acetate
EE: Ethinyl estradiol
DRSP: Ethinyl estradiol-Drospirenone
CRP: c-reactive protein
CPA: Cyproterone acetate
DSG: Desogestrel